Selected research
Market Structure
Global Long-acting rhG-CSF Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Long-acting rhG-CSF market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Long-acting rhG-CSF is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Long-acting rhG-CSF is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Long-acting rhG-CSF is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Long-acting rhG-CSF is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Long-acting rhG-CSF include Yifan Pharmaceutical, CSPC, Sandoz (Novartis), Qilu Pharmaceutical, Mylan, Pfizer, Jiangsu Hengrui Medicine, Fresenius Kabi and Amgen Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Long-acting rhG-CSF market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Long-acting rhG-CSF and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Long-acting rhG-CSF sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Long-acting rhG-CSF market size, projected growth trends, production technologies, key applications, and end-use industries.
Long-acting rhG-CSF Segment by Company
Yifan Pharmaceutical
CSPC
Sandoz (Novartis)
Qilu Pharmaceutical
Mylan
Pfizer
Jiangsu Hengrui Medicine
Fresenius Kabi
Amgen Inc.
Spectrum Pharmaceuticals
Coherus BioSciences, Inc.
Biocon Biologics Inc.
Long-acting rhG-CSF Segment by Type
Long-acting rhG-CSF
Long-acting PEG-rhG-CSF
Long-acting rhG-CSF Segment by Application
Blood Disorders
Neoplastic Diseases
Others
Long-acting rhG-CSF Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting rhG-CSF market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-acting rhG-CSF and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting rhG-CSF.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Long-acting rhG-CSF market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long-acting rhG-CSF manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Long-acting rhG-CSF in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Long-acting rhG-CSF in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Long-acting rhG-CSF
- Long-acting PEG-rhG-CSF
Applications
- Blood Disorders
- Neoplastic Diseases
- Others
Companies covered
- Yifan Pharmaceutical
- CSPC
- Sandoz (Novartis)
- Qilu Pharmaceutical
- Mylan
- Pfizer
- Jiangsu Hengrui Medicine
- Fresenius Kabi
- Amgen Inc.
- Spectrum Pharmaceuticals
- Coherus BioSciences, Inc.
- Biocon Biologics Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Long-acting rhG-CSF Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Long-acting rhG-CSF Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Long-acting rhG-CSF Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Long-acting rhG-CSF Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Long-acting rhG-CSF Market Dynamics
- 2.1 Long-acting rhG-CSF Industry Trends
- 2.2 Long-acting rhG-CSF Industry Drivers
- 2.3 Long-acting rhG-CSF Industry Opportunities and Challenges
- 2.4 Long-acting rhG-CSF Industry Restraints
3 Long-acting rhG-CSF Market by Manufacturers
- 3.1 Global Long-acting rhG-CSF Revenue by Manufacturers (2021-2026)
- 3.2 Global Long-acting rhG-CSF Sales by Manufacturers (2021-2026)
- 3.3 Global Long-acting rhG-CSF Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Long-acting rhG-CSF Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Long-acting rhG-CSF Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Long-acting rhG-CSF Manufacturers, Product Type & Application
- 3.7 Global Long-acting rhG-CSF Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Long-acting rhG-CSF Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Long-acting rhG-CSF Players Market Share by Revenue in 2025
- 3.8.3 2025 Long-acting rhG-CSF Tier 1, Tier 2, and Tier 3
4 Long-acting rhG-CSF Market by Type
- 4.1 Long-acting rhG-CSF Type Introduction
- 4.1.1 Long-acting rhG-CSF
- 4.1.2 Long-acting PEG-rhG-CSF
- 4.2 Global Long-acting rhG-CSF Sales by Type
- 4.2.1 Global Long-acting rhG-CSF Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Long-acting rhG-CSF Sales by Type (2021-2032)
- 4.2.3 Global Long-acting rhG-CSF Sales Market Share by Type (2021-2032)
- 4.3 Global Long-acting rhG-CSF Revenue by Type
- 4.3.1 Global Long-acting rhG-CSF Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Long-acting rhG-CSF Revenue by Type (2021-2032)
- 4.3.3 Global Long-acting rhG-CSF Revenue Market Share by Type (2021-2032)
5 Long-acting rhG-CSF Market by Application
- 5.1 Long-acting rhG-CSF Application Introduction
- 5.1.1 Blood Disorders
- 5.1.2 Neoplastic Diseases
- 5.1.3 Others
- 5.2 Global Long-acting rhG-CSF Sales by Application
- 5.2.1 Global Long-acting rhG-CSF Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Long-acting rhG-CSF Sales by Application (2021-2032)
- 5.2.3 Global Long-acting rhG-CSF Sales Market Share by Application (2021-2032)
- 5.3 Global Long-acting rhG-CSF Revenue by Application
- 5.3.1 Global Long-acting rhG-CSF Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Long-acting rhG-CSF Revenue by Application (2021-2032)
- 5.3.3 Global Long-acting rhG-CSF Revenue Market Share by Application (2021-2032)
6 Global Long-acting rhG-CSF Sales by Region
- 6.1 Global Long-acting rhG-CSF Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Long-acting rhG-CSF Sales by Region (2021-2032)
- 6.2.1 Global Long-acting rhG-CSF Sales by Region (2021-2026)
- 6.2.2 Global Long-acting rhG-CSF Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Long-acting rhG-CSF Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Long-acting rhG-CSF Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Long-acting rhG-CSF Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Long-acting rhG-CSF Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Long-acting rhG-CSF Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Long-acting rhG-CSF Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Long-acting rhG-CSF Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Long-acting rhG-CSF Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Long-acting rhG-CSF Revenue by Region
- 7.1 Global Long-acting rhG-CSF Revenue by Region
- 7.1.1 Global Long-acting rhG-CSF Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Long-acting rhG-CSF Revenue by Region (2021-2026)
- 7.1.3 Global Long-acting rhG-CSF Revenue by Region (2027-2032)
- 7.1.4 Global Long-acting rhG-CSF Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Long-acting rhG-CSF Revenue (2021-2032)
- 7.2.2 North America Long-acting rhG-CSF Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Long-acting rhG-CSF Revenue (2021-2032)
- 7.3.2 Europe Long-acting rhG-CSF Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Long-acting rhG-CSF Revenue (2021-2032)
- 7.4.2 Asia-Pacific Long-acting rhG-CSF Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Long-acting rhG-CSF Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Long-acting rhG-CSF Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Yifan Pharmaceutical
- 8.1.1 Yifan Pharmaceutical Company Information
- 8.1.2 Yifan Pharmaceutical Business Overview
- 8.1.3 Yifan Pharmaceutical Long-acting rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Yifan Pharmaceutical Long-acting rhG-CSF Product Portfolio
- 8.1.5 Yifan Pharmaceutical Recent Developments
- 8.2 CSPC
- 8.2.1 CSPC Company Information
- 8.2.2 CSPC Business Overview
- 8.2.3 CSPC Long-acting rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 CSPC Long-acting rhG-CSF Product Portfolio
- 8.2.5 CSPC Recent Developments
- 8.3 Sandoz (Novartis)
- 8.3.1 Sandoz (Novartis) Company Information
- 8.3.2 Sandoz (Novartis) Business Overview
- 8.3.3 Sandoz (Novartis) Long-acting rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Sandoz (Novartis) Long-acting rhG-CSF Product Portfolio
- 8.3.5 Sandoz (Novartis) Recent Developments
- 8.4 Qilu Pharmaceutical
- 8.4.1 Qilu Pharmaceutical Company Information
- 8.4.2 Qilu Pharmaceutical Business Overview
- 8.4.3 Qilu Pharmaceutical Long-acting rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Qilu Pharmaceutical Long-acting rhG-CSF Product Portfolio
- 8.4.5 Qilu Pharmaceutical Recent Developments
- 8.5 Mylan
- 8.5.1 Mylan Company Information
- 8.5.2 Mylan Business Overview
- 8.5.3 Mylan Long-acting rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Mylan Long-acting rhG-CSF Product Portfolio
- 8.5.5 Mylan Recent Developments
- 8.6 Pfizer
- 8.6.1 Pfizer Company Information
- 8.6.2 Pfizer Business Overview
- 8.6.3 Pfizer Long-acting rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Pfizer Long-acting rhG-CSF Product Portfolio
- 8.6.5 Pfizer Recent Developments
- 8.7 Jiangsu Hengrui Medicine
- 8.7.1 Jiangsu Hengrui Medicine Company Information
- 8.7.2 Jiangsu Hengrui Medicine Business Overview
- 8.7.3 Jiangsu Hengrui Medicine Long-acting rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Jiangsu Hengrui Medicine Long-acting rhG-CSF Product Portfolio
- 8.7.5 Jiangsu Hengrui Medicine Recent Developments
- 8.8 Fresenius Kabi
- 8.8.1 Fresenius Kabi Company Information
- 8.8.2 Fresenius Kabi Business Overview
- 8.8.3 Fresenius Kabi Long-acting rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Fresenius Kabi Long-acting rhG-CSF Product Portfolio
- 8.8.5 Fresenius Kabi Recent Developments
- 8.9 Amgen Inc.
- 8.9.1 Amgen Inc. Company Information
- 8.9.2 Amgen Inc. Business Overview
- 8.9.3 Amgen Inc. Long-acting rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Amgen Inc. Long-acting rhG-CSF Product Portfolio
- 8.9.5 Amgen Inc. Recent Developments
- 8.10 Spectrum Pharmaceuticals
- 8.10.1 Spectrum Pharmaceuticals Company Information
- 8.10.2 Spectrum Pharmaceuticals Business Overview
- 8.10.3 Spectrum Pharmaceuticals Long-acting rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Spectrum Pharmaceuticals Long-acting rhG-CSF Product Portfolio
- 8.10.5 Spectrum Pharmaceuticals Recent Developments
- 8.11 Coherus BioSciences, Inc.
- 8.11.1 Coherus BioSciences, Inc. Company Information
- 8.11.2 Coherus BioSciences, Inc. Business Overview
- 8.11.3 Coherus BioSciences, Inc. Long-acting rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Coherus BioSciences, Inc. Long-acting rhG-CSF Product Portfolio
- 8.11.5 Coherus BioSciences, Inc. Recent Developments
- 8.12 Biocon Biologics Inc.
- 8.12.1 Biocon Biologics Inc. Company Information
- 8.12.2 Biocon Biologics Inc. Business Overview
- 8.12.3 Biocon Biologics Inc. Long-acting rhG-CSF Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Biocon Biologics Inc. Long-acting rhG-CSF Product Portfolio
- 8.12.5 Biocon Biologics Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Long-acting rhG-CSF Value Chain Analysis
- 9.1.1 Long-acting rhG-CSF Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Long-acting rhG-CSF Production Mode & Process
- 9.2 Long-acting rhG-CSF Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Long-acting rhG-CSF Distributors
- 9.2.3 Long-acting rhG-CSF Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst